Vir Biotechnology, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Vir Biotechnology, Inc. (VIR) reported Net Income (Loss) Available to Common Stockholders, Basic of -$65.28 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-03.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-05-03
- Vir Biotechnology, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-03-31 was -$65.28M.
- Vir Biotechnology, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-12-31 was -$115.97M.
- Vir Biotechnology, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-09-30 was -$163.41M, a 193.21% decline year-over-year.
- Vir Biotechnology, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-06-30 was -$194.78M.
- Vir Biotechnology, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$615.06M, a 219.24% decline from fiscal 2022.
- Vir Biotechnology, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was $515.84M, a 2.41% decline from fiscal 2021.
- Vir Biotechnology, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was $528.58M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$65.28M 10-Q · filed 2024-05-03 | -$181.25M derived: sum of 2 quarters · filed 2024-05-03 | -$344.66M derived: sum of 3 quarters · filed 2024-05-03 | -$539.44M derived: sum of 4 quarters · filed 2024-05-03 |
| 2023-12-31 | -$115.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$279.39M derived: sum of 2 quarters · filed 2024-02-26 | -$474.16M derived: sum of 3 quarters · filed 2024-02-26 | -$615.06M 10-K · filed 2024-02-26 |
| 2023-09-30 | -$163.41M 10-Q · filed 2023-11-03 | -$358.19M derived: sum of 2 quarters · filed 2023-11-03 | -$499.09M 10-Q · filed 2023-11-03 | -$600.69M derived: sum of 4 quarters · filed 2024-05-03 |
| 2023-06-30 | -$194.78M 10-Q · filed 2023-08-04 | -$335.68M 10-Q · filed 2023-08-04 | -$437.28M derived: sum of 3 quarters · filed 2024-05-03 | -$261.97M derived: sum of 4 quarters · filed 2024-05-03 |
| 2023-03-31 | -$140.90M 10-Q · filed 2024-05-03 | -$242.50M derived: sum of 2 quarters · filed 2024-05-03 | -$67.19M derived: sum of 3 quarters · filed 2024-05-03 | -$143.68M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | -$101.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $73.71M derived: sum of 2 quarters · filed 2024-02-26 | -$2.78M derived: sum of 3 quarters · filed 2024-02-26 | $515.84M 10-K · filed 2024-02-26 |
| 2022-09-30 | $175.31M 10-Q · filed 2023-11-03 | $98.82M derived: sum of 2 quarters · filed 2023-11-03 | $617.44M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | -$76.49M 10-Q · filed 2023-08-04 | $442.13M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $518.62M 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $528.58M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |